Does dipyrone have any effect on respiratory function in COPD patients?

Respiratory Medicine

Volumn 100, Issue 5, 2006, Pages 828-834

  Gulmez, S Ezgi ^a   Tulunay, F Cankat ^a   Beder, Sumru ^a   Kayacan, Oya ^a   Karnak, Demet ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Bronchodilation; Chronic obstructive pulmonary disease (COPD); Dipyrone (metamizole); Spirometry

Indexed keywords

DIPYRONE;

ADULT; AGED; ARTICLE; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; DYSPNEA; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SPIROMETRY; VOLUNTEER; WHEEZING;

ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIPYRONE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MAXIMAL EXPIRATORY FLOW RATE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 33645852849     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.09.002     Document Type: Article

References (23)

1. ®, Hoechst, 1996.
2. Zicha L., Scheiffarth F., Schmid E., Alms U., and Schott G. Untersuchungen Über Antagonistische Effekte Verschiedener Antiphlogistica Sowie Muskelrelaxantiken Gegen Histamin Und Serotonin. Arzneim Forsch 11 (1961) 598-602
3. Türker K., and Kiran B.K. The antagonistic effect of noramidopyrine methanesulfonate on some pharmacological actions of the synthetic bradykinin. Arzneim Forsch 14 (1964) 1318-1319
4. Gulmez S.E., Gurdal H., and Tulunay F.C. The role of phospholipase C activity in smooth muscle relaxing effect of dipyrone. Basic and Clinical Pharmacology and Toxicology 97 suppl. I (2005) 100 (Proceedings of the 7th Congress of the European association for Clinical Pharmacology and Therapeutics)
5. Brandstätter G. Pharmacological pressure reduction in the human common bile duct. Z Gastroenterol 21 (1983) 168-174
6. Brandstätter G., Kratochvil P., Kalhammer R., and Schinzel S. Influence of spasmolytic analgesic on motility of sphincter oddi. Dig Dis Sci 41 (1996) 1814-1818
7. Schroth H.J., Garth H., Rupp S., and Steinstrasser A. Wirkung Von Metamizole Auf Die Harnwegs-Motilitat. Fortschr Med 104 (1986) 378-382
8. Schroth H.J. Direkte Spasmolytische Wirkung Des Metamizols Auf Die Glatte Musculatur Der Abfuhrenden Harn-Und Gallenwege. Therapiewoche 39 (1989) 1522-1525
9. Schroth H.J., Steinstrasser A., Berberich R., and Kloss G. Investigations on the effect of metamizole on ureteral motility. In: Brune K. (Ed). Agents and actions, supplements, vol. 19. 100 years of pyrazolone drugs (1986), Birkhauseer Verlag, Basel 177-188
10. Hady S. Dipyrone in asthma. Br Med J 1 5855 (1973) 744
11. Resta O., Foschino-Barbaro M.P., Carnimeo N., Bavoso P., and Picca V. Asthma relieved by acetylsalicylic acid and nonsteroid anti-inflammatory drugs. Respiration 46 (1984) 121-127
12. World Health Organisation. World Health Organisation Report 2000. Geneva; World Health Organisation; 2001.
13. Lopez A.D., and Muray C.C. The global burden of disease, 1990-2020. Nat Med 4 (1998) 1241-1243
14. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/Who Workshop Report. Bethesda: National Heart, Lung, and Blood Institute. Update of the Management Sections, GOLD Website www.goldcopd.com, date updated: 1 July 2003.
15. Pauwels R.A. National and international guidelines for COPD: The need for evidence. Chest 117 (2000) 20s-22s
16. Celli B.R. The importance of spirometry in COPD and asthma: effect on approach to management. Chest 117 (2000) 15s-19s
17. Pearson M.G., Alderslade R., Allen S.C., Apps M.C.P., Barnes G., Bellamy D., et al. Guidelines for COPD, British Thoracic Society. Thorax 52 Suppl. 5 (1997) S1
18. Calvarley P.M., Burge P.S., Spencer S., Andersen J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 (2003) 659-664
19. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/Who Workshop Report. Bethesda: National Heart, Lung, and Blood Institute, NIH Publication 2001, No 2701, p. 1-100.
20. Barnes P.J. Chronic obstructive pulmonary disease. N Engl J Med 343 (2003) 269-280
21. Sturtevant J. NSAID-induced bronchospasm-a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority. N Z Dent J 95 421 (1990) 84
22. Zikowski D., Hord A.H., Haddox J.D., and Glascock J. Ketorolac-induced bronchospasm. Anesth Analg 76 2 (1993) 417-419
23. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30 2 (1981) 239-245